StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a research report released on Tuesday morning. The firm issued a hold rating on the stock.

Separately, JMP Securities reiterated a "market outperform" rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

NASDAQ:DBVT traded up $0.07 during mid-day trading on Tuesday, hitting $7.98. 58,046 shares of the stock were exchanged, compared to its average volume of 181,088. The firm's 50-day simple moving average is $5.45 and its 200 day simple moving average is $4.29. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $8.50. The stock has a market capitalization of $164.16 million, a price-to-earnings ratio of -1.77 and a beta of -0.08.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The business had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. On average, analysts predict that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.